{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T16:48:52Z","timestamp":1787676532788,"version":"build-2784847793"},"reference-count":97,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Individuals with hematological malignancies (HMs) are at a high risk of invasive pneumococcal disease due to underlying malignancy and subsequent immunosuppressive anticancer therapy. Early management of pneumococcal infections is crucial for reducing morbidity and mortality in this vulnerable patient subgroup. In this study, we aim to review the current evidence and recommendations regarding the use of pneumococcal conjugate vaccines (PCVs) in patients with HMs and develop a consensus document on the optimal timing and patient profiles who can benefit from them.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The modified Delphi consensus method was used for achieving consensus. The panel comprised a scientific committee of six experts from India. Questions were drafted for discussion around: (i) the risk and consequences of pneumococcal disease in HMs; (ii) barriers to pneumococcal vaccination in the hemato-oncology clinical setting; and (iii) evidence and optimal timing of pneumococcal vaccines in HMs. The questionnaire was shared with the panel through an online survey platform (Delphi round 1). The consensus level was classified as high (\u226580%), moderate (60%\u201379%), and low (&amp;lt; 60%). A Delphi round 2 meeting was conducted to discuss the questions that received near or no consensus to reach an agreement. The final draft of consensus statements was circulated among the experts for approval.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Pneumonia with or without bacteremia and bacteremia without foci of infection are the most frequently reported clinical presentations of pneumococcal infections in patients with HMs. A high risk of pneumococcal disease has been observed in patients with multiple myeloma (MM), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and chronic lymphocytic leukemia (CLL). Priming with PCV enhances the response to pneumococcal polysaccharide vaccine 23 (PPSV23) in patients with HMs. Experts agreed that PCV is beneficial and can be strongly recommended in patients with CLL, MM, and patients undergoing hematopoietic stem cell transplantation. Children with acute lymphoblastic leukemia (ALL) would benefit from systematic revaccination with PCV after chemotherapy. The evidence is inadequate to consistently recommend pneumococcal vaccination to all patients with lymphoma, AML, and adults with ALL.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This expert consensus will guide clinicians on the recommended approach for administering pneumococcal vaccination to patients with HMs.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1546641","type":"journal-article","created":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T04:14:43Z","timestamp":1746072883000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Preventing pneumococcal infections in patients with hematological malignancies: a review of evidence and recommendations based on modified Delphi consensus"],"prefix":"10.3389","volume":"15","author":[{"given":"Tulika","family":"Seth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer","family":"Melinkeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuphan Kanti","family":"Dolai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jina","family":"Bhattacharyya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Sidharthan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prantar","family":"Chakrabarti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaithanya","family":"Malalur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santosh","family":"Taur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,1]]},"reference":[{"key":"B1","unstructured":"Pneumococcal disease"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa090","article-title":"Differences and temporal changes in risk of invasive pneumococcal disease in adults with hematological Malignancies: results from a nationwide 16-year cohort study","volume":"72","author":"Andersen","year":"2021","journal-title":"Clin Infect Dis"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2021.03.072","article-title":"Invasive pneumococcal disease among adults with hematological and solid organ Malignancies: A population-based cohort study","volume":"106","author":"Garcia Garrido","year":"2021","journal-title":"Int J Infect Dis"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268810000919","article-title":"Increased risk of invasive pneumococcal disease in haematological and solid-organ Malignancies","volume":"138","author":"Wong","year":"2010","journal-title":"Epidemiol Infect"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-056986","article-title":"Association between PCV13 pneumococcal vaccination and risk of hospital admissions due to pneumonia or sepsis among patients with haematological Malignancies: a single-centre retrospective cohort study in Israel","volume":"12","author":"Draliuk","year":"2022","journal-title":"BMJ Open"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.4103\/crst.crst_156_21","article-title":"Vaccination practices, efficacy, and safety in adults with cancer: A narrative review","volume":"4","author":"Sarkar","year":"2021","journal-title":"Cancer Res Stat Treat"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2022.12.003","article-title":"Rates of influenza and pneumococcal vaccination and correlation with survival in multiple myeloma patients","volume":"23","author":"Thompson","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B8","doi-asserted-by":"publisher","first-page":"52","DOI":"10.4103\/crst.crst_29_23","article-title":"Uptake of vaccination in older Indian patients with cancer: A cross-sectional observational study","volume":"6","author":"Sabu","year":"2023","journal-title":"Cancer Res Stat Treat"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.21.287390","article-title":"Vaccination coverage among older adults: a population-based study in India","volume":"100","author":"Abbas Rizvi","year":"2022","journal-title":"Bull World Health Organ"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.5662\/wjm.v11.i4.116","article-title":"Delphi methodology in healthcare research: How to decide its appropriateness","volume":"11","author":"Nasa","year":"2021","journal-title":"World J Methodol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.jpainsymman.2011.09.009","article-title":"Consensus building in palliative care: A Europe-wide delphi study on common understandings and conceptual differences","volume":"44","author":"J\u00fcnger","year":"2012","journal-title":"J Pain Symptom Manage"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1159\/000353617","article-title":"AGO recommendations for diagnosis and treatment of patients with early breast cancer: update 2013","volume":"8","author":"Scharl","year":"2013","journal-title":"Breast Care Basel Switz"},{"key":"B13","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1186\/s12879-016-1648-2","article-title":"Epidemiology of invasive pneumococcal infections: manifestations, incidence and case fatality rate correlated to age, gender and risk factors","volume":"16","author":"Backhaus","year":"2016","journal-title":"BMC Infect Dis"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1177\/1179548419862790","article-title":"Streptococcus pneumoniae as a cause of community-acquired pneumonia in Indian adolescents and adults: A systematic review and meta-analysis","volume":"13","author":"Ghia","year":"2019","journal-title":"Clin Med Insights Circ Respir Pulm Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jclinepi.2012.04.006","article-title":"Invasive pneumococcal disease associated with high case fatality in India","volume":"66","author":"Thomas","year":"2013","journal-title":"J Clin Epidemiol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmii.2018.03.004","article-title":"Invasive pneumococcal disease in Indian adults: 11 years\u2019 experience","volume":"52","author":"Jayaraman","year":"2019","journal-title":"J Microbiol Immunol Infect"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ803","article-title":"Invasive pneumococcal disease among immunocompromised persons: implications for vaccination programs","volume":"62","author":"Shigayeva","year":"2016","journal-title":"Clin Infect Dis"},{"key":"B18","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.canep.2013.10.009","article-title":"Community-acquired infections and their association with myeloid Malignancies","volume":"38","author":"Titmarsh","year":"2014","journal-title":"Cancer Epidemiol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30601-7","article-title":"Vaccination of patients with haematological Malignancies who did not have transplantations: guidelines from the 2017 European Conference on Infections in Leukaemia (ECIL 7)","volume":"19","author":"Mikulska","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12030958","article-title":"Outcomes and prognostic factors in critical patients with hematologic Malignancies","volume":"12","author":"Chen","year":"2023","journal-title":"J Clin Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"R155","DOI":"10.1186\/cc11471","article-title":"Epidemiology and outcome of severe pneumococcal pneumonia admitted to intensive care unit: a multicenter study","volume":"16","author":"Mongardon","year":"2012","journal-title":"Crit Care"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1179\/1607845414Y.0000000206","article-title":"Hematologic Malignancies in the medical intensive care unit \u2013 Outcomes and prognostic factors","volume":"20","author":"Grgi\u0107 Medi\u0107","year":"2015","journal-title":"Hematology"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix739","article-title":"Trends in invasive pneumococcal disease in cancer patients after the introduction of 7-valent pneumococcal conjugate vaccine: A 20-year longitudinal study at a major urban cancer center","volume":"66","author":"Lee","year":"2018","journal-title":"Clin Infect Dis"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/173.1.256","article-title":"Pneumococcal conjugate vaccine primes for antibody responses to polysaccharide pneumococcal vaccine after treatment of hodgkin\u2019s disease","volume":"173","author":"Chan","year":"1996","journal-title":"J Infect Dis"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1136\/adc.2010.198416","article-title":"Humoral response to conjugate pneumococcal vaccine in paediatric oncology patients","volume":"97","author":"Cheng","year":"2012","journal-title":"Arch Dis Child"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30764","article-title":"Immunogenicity and safety of single-dose, 13-valent pneumococcal conjugate vaccine in pediatric and adolescent oncology patients","volume":"123","author":"Hung","year":"2017","journal-title":"Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2022.01.056","article-title":"Immunogenicity and safety of routine 13-valent pneumococcal conjugate vaccination outside recommended age range in patients with hematological Malignancies and solid tumors","volume":"40","author":"Takeshita","year":"2022","journal-title":"Vaccine"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.1999.1088","article-title":"Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma","volume":"82","author":"Robertson","year":"2000","journal-title":"Br J Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0463.2012.02922.x","article-title":"Serologic response to a 23-valent pneumococcal vaccine administered prior to autologous stem cell transplantation in patients with multiple myeloma","volume":"120","author":"Hinge","year":"2012","journal-title":"APMIS"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2018.1534516","article-title":"Response to PCV13 vaccination in patients with multiple myeloma versus healthy controls","volume":"15","author":"Mustafa","year":"2019","journal-title":"Hum Vaccines Immunother"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2253","article-title":"Response to pneumococcal vaccination in multiple myeloma","volume":"8","author":"Renaud","year":"2019","journal-title":"Cancer Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-1221","article-title":"Lenalidomide-induced immunomodulation in multiple myeloma: impact on vaccines and antitumor responses","volume":"18","author":"Noonan","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.12.795","article-title":"Revaccination after autologous hematopoietic stem cell transplantation is safe and effective in patients with multiple myeloma receiving lenalidomide maintenance","volume":"24","author":"Palazzo","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.05.024","article-title":"Clinical efficacy of pneumococcal vaccination in multiple myeloma patients on novel agents: Results of a prospective clinical study","volume":"38","author":"Stoma","year":"2020","journal-title":"Vaccine"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz965","article-title":"Thirteen-valent pneumococcal conjugate vaccine in children with acute lymphoblastic leukemia: protective immunity can be achieved on completion of treatment","volume":"71","author":"Bate","year":"2020","journal-title":"Clin Infect Dis"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28944","article-title":"Pneumococcal vaccination during chemotherapy in children treated for acute lymphoblastic leukemia","volume":"68","author":"Dorval","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa163","article-title":"Waning vaccine immunity and vaccination responses in children treated for acute lymphoblastic leukemia: A canadian immunization research network study","volume":"71","author":"Top","year":"2020","journal-title":"Clin Infect Dis"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1136\/adc.2009.176271","article-title":"Serotype-specific pneumococcal antibody concentrations in children treated for acute leukaemia: Table\u00a01","volume":"97","author":"Patel","year":"2012","journal-title":"Arch Dis Child"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(00)00409-6","article-title":"Antibody responses to pneumococcal and haemophilus vaccinations in patients with B-cell chronic lymphocytic leukaemia","volume":"19","author":"Hartkamp","year":"2001","journal-title":"Vaccine"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02882.x","article-title":"Response to vaccination against different types of antigens in patients with chronic lymphocytic leukaemia","volume":"114","author":"Sinisalo","year":"2001","journal-title":"Br J Haematol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23561","article-title":"Multiple\u2010dose granulocyte\u2010macrophage\u2013colony\u2010stimulating factor plus 23\u2010valent polysaccharide pneumococcal vaccine in patients with chronic lymphocytic leukemia: A prospective, randomized trial of safety and immunogenicity","volume":"113","author":"Safdar","year":"2008","journal-title":"Cancer"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.10.053","article-title":"Antibody response to 7-valent conjugated pneumococcal vaccine in patients with chronic lymphocytic leukaemia","volume":"26","author":"Sinisalo","year":"2007","journal-title":"Vaccine"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0114966","article-title":"Antibody and plasmablast response to 13-valent pneumococcal conjugate vaccine in chronic lymphocytic leukemia patients \u2013 preliminary report","volume":"9","author":"Pasiarski","year":"2014","journal-title":"PloS One"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0884-z","article-title":"Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL)","volume":"35","author":"Mauro","year":"2021","journal-title":"Leukemia"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14855","article-title":"Lack of adequate pneumococcal vaccination response in chronic lymphocytic leukaemia patients receiving ibrutinib","volume":"182","author":"Andrick","year":"2018","journal-title":"Br J Haematol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.05.012","article-title":"Pneumococcal conjugate vaccine triggers a better immune response than pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia A randomized study by the Swedish CLL group","volume":"36","author":"Svensson","year":"2018","journal-title":"Vaccine"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2018.1436424","article-title":"Antibody persistence after pneumococcal conjugate vaccination in patients with chronic lymphocytic leukemia","volume":"14","author":"Lindstr\u00f6m","year":"2018","journal-title":"Hum Vaccines Immunother"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-11-465039","article-title":"Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling","volume":"122","author":"De Lavallade","year":"2013","journal-title":"Blood"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1990.tb00426.x","article-title":"A longitudinal study of class and subclass antibody response to pneumococcal vaccination in splenectomized individuals with special reference to patients with Hodgkin\u2019s disease","volume":"45","author":"Grimfors","year":"1990","journal-title":"Eur J Haematol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1128\/cdli.4.6.635-638.1997","article-title":"Antibody responses of splenectomized patients with non-Hodgkin\u2019s lymphoma to immunization with polyvalent pneumococcal vaccines","volume":"4","author":"Petrasch","year":"1997","journal-title":"Clin Diagn Lab Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2004.01312.x","article-title":"A prospective study on antibody response to repeated vaccinations with pneumococcal capsular polysaccharide in splenectomized individuals with special reference to Hodgkin\u2019s lymphoma","volume":"255","author":"Landgren","year":"2004","journal-title":"J Intern Med"},{"key":"B52","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.vaccine.2005.07.054","article-title":"Poor antibody response to pneumococcal polysaccharide vaccination suggests increased susceptibility to pneumococcal infection in splenectomized patients with hematological diseases","volume":"24","author":"Cherif","year":"2006","journal-title":"Vaccine"},{"key":"B53","doi-asserted-by":"publisher","first-page":"828","DOI":"10.7326\/0003-4819-123-11-199512010-00003","article-title":"Antibody responses to polysaccharide and polysaccharide-conjugate vaccines after treatment of hodgkin disease","volume":"123","author":"Molrine","year":"1995","journal-title":"Ann Intern Med"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.08.011","article-title":"Pneumococcal conjugate vaccine does not induce humoral response when administrated within the six months after CD19 CAR T-cell therapy","volume":"29","author":"Lee","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"B55","unstructured":"NCCN clinical practice guidelines for prevention and treatment of cancer-related infections (version 3, 2024)\n          \n          \n          \n          2024"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00032","article-title":"Vaccination of adults with cancer: ASCO guideline","volume":"42","author":"Kamboj","year":"2024","journal-title":"J Clin Oncol"},{"key":"B57","unstructured":"Recommended child and adolescent immunization schedule for ages 18 years or younger"},{"key":"B58","unstructured":"Pneumococcal vaccine timing for adults"},{"key":"B59","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.4103\/lungIndia.lungIndia_272_20","article-title":"Clinical practice guidelines 2019: Indian consensus-based recommendations on pneumococcal vaccination for adults","volume":"37","author":"Dhar","year":"2020","journal-title":"Lung India"},{"key":"B60","unstructured":"Indian medical association immunisation guideline book\n          \n          2018"},{"key":"B61","unstructured":"Pneumococcal conjugate vaccines"},{"key":"B62","unstructured":"Indian guidelines for vaccination in older adults"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit684","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin Infect Dis"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1007\/s13312-019-1678-0","article-title":"Immunization of children with cancer in India treated with chemotherapy - consensus guideline from the pediatric hematology-oncology chapter and the advisory committee on vaccination and immunization practices of the Indian academy of pediatrics","volume":"56","author":"Moulik","year":"2019","journal-title":"Indian Pediatr"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy117","article-title":"Anti-infective vaccination strategies in patients with hematologic Malignancies or solid tumors-Guideline of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO)","volume":"29","author":"Rieger","year":"2018","journal-title":"Ann Oncol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.micinf.2017.08.005","article-title":"Pneumococcal polysaccharide vaccination in allogeneic hematopoietic stem cell transplantation recipients: a prospective single-center study","volume":"19","author":"Okinaka","year":"2017","journal-title":"Microbes Infect"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.06.012","article-title":"Response to pneumococcal (PNCRM7) and haemophilus influenzae conjugate vaccines (HIB) in pediatric and adult recipients of an allogeneic hematopoietic cell transplantation (alloHCT)","volume":"14","author":"Pao","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-06-032284","article-title":"Pneumococcal conjugate vaccine provides early protective antibody responses in children after related and unrelated allogeneic hematopoietic stem cell transplantation","volume":"109","author":"Meisel","year":"2007","journal-title":"Blood"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.42","article-title":"Long-term persistence of the immune response to antipneumococcal vaccines after Allo-SCT: 10-year follow-up of the EBMT-IDWP01 trial","volume":"50","author":"Cordonnier","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-03-0832","article-title":"Donor immunization with pneumococcal conjugate vaccine and early protective antibody responses following allogeneic hematopoietic cell transplantation","volume":"101","author":"Molrine","year":"2003","journal-title":"Blood"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2004.12.330","article-title":"Protective antibody responses to pneumococcal conjugate vaccine after autologous hematopoietic stem cell transplantation","volume":"11","author":"Antin","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1086\/523583","article-title":"A randomized, double-blind trial of pneumococcal vaccination in adult allogeneic stem cell transplant donors and recipients","volume":"45","author":"Kumar","year":"2007","journal-title":"Clin Infect Dis"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.11.053","article-title":"Long-term pneumococcal vaccine immunogenicity following allogeneic hematopoietic stem cell transplantation","volume":"37","author":"Langedijk","year":"2019","journal-title":"Vaccine"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ287","article-title":"Immunogenicity, safety, and tolerability of 13-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine in recipients of allogeneic hematopoietic stem cell transplant aged \u22652 years: an open-label study","volume":"61","author":"Cordonnier","year":"2015","journal-title":"Clin Infect Dis"},{"key":"B75","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1002\/ajh.26493","article-title":"Immunogenicity of a 5\u2010dose pneumococcal vaccination schedule following allogeneic hematopoietic stem cell transplantation","volume":"97","author":"Garcia Garrido","year":"2022","journal-title":"Am J Hematol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2022.12.007","article-title":"Immunogenicity of three versus four doses of 13-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine in allogeneic haematopoietic stem cell transplantation recipients: a multicentre, randomized controlled trial","volume":"29","author":"Okinaka","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.10.008","article-title":"Vaccination responses and lymphocyte subsets after autologous stem cell transplantation","volume":"25","author":"Van Der Velden","year":"2007","journal-title":"Vaccine"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz1168","article-title":"Antipneumococcal seroprotection years after vaccination in allogeneic hematopoietic cell transplant recipients","volume":"71","author":"Robin","year":"2020","journal-title":"Clin Infect Dis"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.10.006","article-title":"Clinical effectiveness of conjugate pneumococcal vaccination in hematopoietic stem cell transplantation recipients","volume":"26","author":"Roberts","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1086\/598324","article-title":"Randomized Study of Early versus Late Immunization with Pneumococcal Conjugate Vaccine after Allogeneic Stem Cell Transplantation","volume":"48","author":"Cordonnier","year":"2009","journal-title":"Clin Infect Dis"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2009.364","article-title":"Relationship between IgG titers and opsonocytophagocytic activity of anti-pneumococcal antibodies after immunization with the 7-valent conjugate vaccine in allogeneic stem cell transplant","volume":"45","author":"Cordonnier","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.01.025","article-title":"Immune response to the 23-valent polysaccharide pneumococcal vaccine after the 7-valent conjugate vaccine in allogeneic stem cell transplant recipients: Results from the EBMT IDWP01 trial","volume":"28","author":"Cordonnier","year":"2010","journal-title":"Vaccine"},{"key":"B83","unstructured":"National guidelines for hematopoietic cell transplantation"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30600-5","article-title":"Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7)","volume":"19","author":"Cordonnier","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-016-2711-1","article-title":"Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016","volume":"95","author":"Ullmann","year":"2016","journal-title":"Ann Hematol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10071164","article-title":"Enabling factors, barriers, and perceptions of pneumococcal vaccination strategy implementation: A qualitative study","volume":"10","author":"Huang","year":"2022","journal-title":"Vaccines"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/s0264-410x(01)00463-7","article-title":"Adult pneumococcal vaccination: a review of physician and patient barriers","volume":"20","author":"Mieczkowski","year":"2002","journal-title":"Vaccine"},{"key":"B88","unstructured":"Pneumococcal vaccination"},{"key":"B89","unstructured":"Pneumococcal disease"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens9040259","article-title":"A systematic review of studies published between 2016 and 2019 on the effectiveness and efficacy of pneumococcal vaccination on pneumonia and invasive pneumococcal disease in an elderly population","volume":"9","author":"Berild","year":"2020","journal-title":"Pathog Basel Switz"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens12050732","article-title":"Systematic review and meta-analysis of the efficacy and effectiveness of pneumococcal vaccines in adults","volume":"12","author":"Farrar","year":"2023","journal-title":"Pathogens"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.12.004","article-title":"Impact and cost effectiveness of pneumococcal conjugate vaccine in India","volume":"37","author":"Krishnamoorthy","year":"2019","journal-title":"Vaccine"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.169","article-title":"Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine","volume":"307","author":"Smith","year":"2012","journal-title":"JAMA"},{"key":"B94","unstructured":"National operational guidelines on the introduction of pneumococcal conjugate vaccine, India\n          \n          \n          \n          2017"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1099\/mgen.0.000645","article-title":"Streptococcus pneumoniae genomic datasets from an Indian population describing pre-vaccine evolutionary epidemiology using a whole genome sequencing approach","volume":"7","author":"Nagaraj","year":"2021","journal-title":"Microb Genomics"},{"key":"B96","unstructured":"ICMR Annual Report 2021 (Antimicrobial resistance research and surveillance network)"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.06.079","article-title":"Serotype distribution and antimicrobial susceptibility pattern in children \u2264 5 years with invasive pneumococcal disease in India \u2013 A systematic review","volume":"35","author":"Singh","year":"2017","journal-title":"Vaccine"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1546641\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T04:14:51Z","timestamp":1746072891000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1546641\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,1]]},"references-count":97,"alternative-id":["10.3389\/fonc.2025.1546641"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1546641","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,1]]},"article-number":"1546641"}}